FDA's Unlikely Defenders
This article was originally published in RPM Report
The primacy of FDA-approved labeling has an unlikely advocate. The Washington Legal Foundation is joining the EPO coverage dispute to tell CMS not to step into FDA’s turf.
You may also be interested in...
CMS’ coverage of cancer drugs isn’t as automatic as you think. Here’s how the Medicare agency sees it.
Amgen, J&J and a host of supporters urged CMS to wait until FDA completes its safety review of EPO before acting to limit coverage. CMS is having none of it.
Amgen and J&J have billions of dollars at stake in the battle to convince CMS to change its coverage proposal for EPO in cancer patients. Win or lose, their efforts will be a valuable case study for any other manufacturer that fi nds itself facing an adverse reimbursement policy.